MedImmune is looking to UCSF researchers to feed its drug pipeline. In a three-year deal with the University of California, San Francisco’s Clinical and Translational Science Institute, the biologics R&D unit of AstraZeneca hopes to spot potential early-research drugs for a wide-range of diseases, including cancer, heart disease, metabolic diseases, neuroscience and infectious diseases. Financial terms of the deal were not disclosed.
Help employers find you! Check out all the jobs and post your resume.
